Magazine Article | May 1, 2023

How To Overcome Headwinds In Securing Funding For Rare Disease Research

Source: Life Science Leader

By Giacomo Chiesi

In recent months drug developers have seen, and many have experienced, significant headwinds in securing funding, as evidenced by workforce layoffs as well as challenges in the ability of publicly listed biotech companies to raise money or for privately listed biotech companies to initiate a public offering.

The headwinds are possibly even stronger for drug developers in rare and orphan diseases, given they target very small markets and often must conduct expensive and sometimes lengthy clinical trials with complex manufacturing processes. VCs and other investors typically prioritize assets that target large patient populations and have broad applicability, given the higher prevalence might present more attractive “exits” or clearer liquidity events. As a result, many potential rare disease treatments languish due to lack of funding.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader